Resources Repository
-
ArticlePublication 2022Economic Evaluations of Health System Strengthening Activities
Health system strengthening (HSS) activities should accompany disease-targeting interventions in low/middle-income countries (LMICs). Economic evaluations …
Health system strengthening (HSS) activities should accompany disease-targeting interventions in low/middle-income countries (LMICs). Economic evaluations provide information on how these types of investment might best be balanced but can be challenging. This paper conducted a systematic review to evaluate how researchers address these economic evaluation challenges. The authors searches produced 1978 studies, out of which they included 36. Most studies used data from prospective trials and calculated cost-effectiveness directly from these trial inputs, rather than…
Economics/Finance | Global | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine -
ArticlePublication 2022Economic Value of Clinical Artificial Intelligence
Artificial intelligence (AI) is increasingly used in clinical applications. Nevertheless, its flexibility and difficulties around …
Artificial intelligence (AI) is increasingly used in clinical applications. Nevertheless, its flexibility and difficulties around collecting data on its clinical impacts make value assessment challenging. This article uses a value framework as the basis for assessing how AI may create value depending on how it is used. Authors also provide advice to health economists seeking to model AI’s clinical impacts. There are multiple ways that AI challenges traditional health technology assessment methodology. Authors highlight several…
Economics/Finance | Global | Value of Information | Technology Assessment | Science/Technology -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Economics/Finance | Global | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Economics/Finance | Global | Health Outcomes | Evidence Synthesis | Technology Assessment | Infectious Diseases | Policy/Regulation | Global Governance | Clinical Care | Business/Industry | Health/Medicine -
ArticlePublication 2017Costing of National STI Program Implementation, 2016-2021
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) …
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) 2016–2021 aiming to reduce curable STIs by 90% by 2030. This analysis costed scaling-up priority interventions to achieve coverage targets. Strategy-targeted declines in Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum and Trichomonas vaginalis were applied to WHO-estimated regional burdens at 2012 levels. Case management was costed for the curable STIs, symptomatic Herpes Simplex Virus 2 (HSV-2), and non-STI vaginal syndromes, with incrementally expanding diagnoses. Service…
Costing Methods | Economics/Finance | Global | Evidence Synthesis | Infectious Diseases | Clinical Care | Health/Medicine -
ArticlePublication 2017Policy Makers, the International Community and the Population: Case Study on HIV/AIDS
A four-period game is developed between a policy maker, the international community, and the population. …
A four-period game is developed between a policy maker, the international community, and the population. This research supplements, through implementing strategic interaction, earlier research analyzing "one player at a time." The first two players distribute funds between preventing and treating diseases. The population reacts by degree of risky behavior which may cause no disease, disease contraction, recovery, sickness/death. More funds to prevention implies less disease contraction but higher death rate given disease contraction. The cost…
Mathematical Models | Economics/Finance | Global | Decision Psychology | Priority Setting/Ethics | Infectious Diseases | Health Systems | Global Governance | Government/Law | Health/Medicine -
OrganizationWeb Portal 2024Immunization Costing Action Network (ICAN)
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of …
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of immunization delivery cost information. They are building country capacity around the generation of cost information to solve program and policy challenges and working with countries to improve interpretation and translation of cost information for country decision-making processes and routine planning and budgeting. The ICAN is comprised of four-member countries (India, Indonesia, Tanzania, and Vietnam) with country teams that include health…
Costing Methods | Economics/Finance | Global | Infectious Diseases | Child/Nutrition | Health Systems | Business/Industry | Health/Medicine | Science/Technology -
Tutorial/PrimerPublication, Teaching Resource 2016Cost per DALY Thresholds and Health Opportunity Costs
This policy brief aims to explain the cost per DALY threshold and the concepts of …
This policy brief aims to explain the cost per DALY threshold and the concepts of health opportunity costs, especially aimed at low and middle-income countries. The authors state that an assessment of health opportunity costs is required if the best use is to be made of health and healthcare resources. This requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the…
Economics/Finance | Global | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2016Costs and Benefits of Integrated RMNCH
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, …
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, newborn and child health interventions in countries with high child and maternal mortality to demonstrate that very high returns can be achieved through this investment and to underscore the importance of an accurate assessment of those returns. This includes the full range of costs involved in delivering integrated care and the full range of benefits that flow from the interventions.…
Costing Methods | Economics/Finance | Global | Priority Setting/Ethics | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Health/Medicine